These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22298228)

  • 21. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs for ADHD.
    Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacological management of attention-deficit hyperactivity disorder.
    Reeves G; Schweitzer J
    Expert Opin Pharmacother; 2004 Jun; 5(6):1313-20. PubMed ID: 15163276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options.
    Hodgkins P; Shaw M; Coghill D; Hechtman L
    Eur Child Adolesc Psychiatry; 2012 Sep; 21(9):477-92. PubMed ID: 22763750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulant therapy in attention deficit/hyperactivity disorder.
    Baldwin RL
    J Ark Med Soc; 2003 Dec; 100(6):203-6. PubMed ID: 14661403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amphetamine-induced chorea in attention deficit-hyperactivity disorder.
    Morgan JC; Winter WC; Wooten GF
    Mov Disord; 2004 Jul; 19(7):840-842. PubMed ID: 15254949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
    Knight M
    Pediatrics; 2007 Jan; 119(1):154-5. PubMed ID: 17200281
    [No Abstract]   [Full Text] [Related]  

  • 28. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Hammerness PG; Biederman J; Kwon A; Spencer TJ; Clark S; Scott M; Podolski A; Ditterline JW; Morris MC; Moore H
    J Clin Psychiatry; 2005 Feb; 66(2):253-9. PubMed ID: 15705013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing stimulant medication for attention-deficit/hyperactivity disorder: an update.
    Wender EH
    Pediatr Rev; 2002 Jul; 23(7):234-6. PubMed ID: 12093933
    [No Abstract]   [Full Text] [Related]  

  • 30. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
    Stein MA; Waldman ID; Charney E; Aryal S; Sable C; Gruber R; Newcorn JH
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):581-8. PubMed ID: 22136094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug treatment of ADHD - tenuous scientific basis.
    Vogt H; Lunde C
    Tidsskr Nor Laegeforen; 2018 Jan; 138(2):. PubMed ID: 29357653
    [No Abstract]   [Full Text] [Related]  

  • 33. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.
    Greenhill LL; Pliszka S; Dulcan MK; Bernet W; Arnold V; Beitchman J; Benson RS; Bukstein O; Kinlan J; McClellan J; Rue D; Shaw JA; Stock S;
    J Am Acad Child Adolesc Psychiatry; 2002 Feb; 41(2 Suppl):26S-49S. PubMed ID: 11833633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Encouraging news about ADHD drugs and heart risk in adults.
    Harv Ment Health Lett; 2012 Mar; 28(9):7. PubMed ID: 22474711
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
    Awudu GA; Besag FM
    Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects.
    Golmirzaei J; Mahboobi H; Yazdanparast M; Mushtaq G; Kamal MA; Hamzei E
    Curr Pharm Des; 2016; 22(5):590-4. PubMed ID: 26601963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J
    Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
    Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A
    Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in Stimulant Medication Use in Commercially Insured Youths and Adults, 2010-2014.
    Burcu M; Zito JM; Metcalfe L; Underwood H; Safer DJ
    JAMA Psychiatry; 2016 Sep; 73(9):992-3. PubMed ID: 27331629
    [No Abstract]   [Full Text] [Related]  

  • 40. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.